专利号:US-2009234121-A1 优先权日:2008-01-16 标 题 :Tridentate (nnc) catalysts for the selective oxidation of hydrocarbons 发明人:PERIANA ROY A; GODDARD III WILLIAM A; OXGAARD JONAS; YOUNG KENNETH 权利人:PERIANA ROY A; GODDARD III WILLIAM A; OXGAARD JONAS; YOUNG KENNETH 摘要:The synthesis of discrete, air, protic, and thermally stable transition metal NNC complexes that catalyze the CH activation and functionalization of alkanes and arenes is disclosed. Methods for the selective conversion of methane to methanol or methyl esters in acidic and neutral media are disclosed.
专利号:US-7652178-B2 优先权日:2007-02-26 标题:Perfluoroparacyclophane and methods of synthesis and use thereof 发明人:DOLBIER JR WILLIAM R; XIE PUHUI; KUMAR RAKESH 权利人:SPECIALTY COATING SYSTEMS INC 摘要:A composition comprising perfluoro-[2,2]-paracyclophane dimer compound is disclosed. The synthesis reaction of the paracyclophane dimer from 1,4-bis(chlorodifluoromethane)-2,3,5,6-tetrafluorobenzene involves heating in the presence of a metal catalyst and a solvent. A perfluorinated paraxylylene coating formed from the perfluorinated paracyclophane dimer is also disclosed.
专利号:EP-1641453-B1 优先权日:2003-06-25 标题 :Product containing at least one phosphatase cdc25 inhibitor combined with at least one other anticancer agent 发明人:PREVOST GREGOIRE; BREZAK PANNETIER MARIE-CHRISTINE; DIOLEZ CHRISTIAN 权利人:IPSEN PHARMA 摘要:The invention relates to a product containing at least one phosphatase Cdc25 inhibitor combined with at least one other anticancer agent for simultaneous, separate or staggered therapeutic use during treatment for cancer. According to the invention, the other anticancer agent is preferably selected from: DNA base analogs such as 5-fluorouracil; inhibitors of type I and/or type II topoisomerases, such as camptothecin and the analogs thereof, doxorubicin or amsacrine; compounds interacting with the cellular spindle, for example, paclitaxel (Taxol); compounds acting on the cytoskeleton, such as vinblastine; inhibitors of the transduction of the signal passing via the heterotrimeric G proteins; prenyltransferase inhibitors, and especially farnesyltransferase inhibitors; cyclin-dependent kinase (CDKs) inhibitors; alkylating agents such as cisplatin; folic acid antagonists such as methotrexate; and inhibitors of DNA synthesis and cellular division, such as mitomycin C. The invention also relates to (1R)-1-[({(2R)-2-amino--3-[(8S)-8-(cyclohexylmethyl)-2-phenyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]--3-oxopropyl}dithio)methyl]-2-[(8S)-8-(cyclohexylmethyl)-2-phenyl--5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl]-2-oxoethylamine, or the pharmaceutically acceptable salts thereof, that can be used as anticancer agents.
专利号:US-2008207961-A1 优先权日:2007-02-26 标 题 :Perfluoroparacyclophane and methods of synthesis and use thereof
专利号:US-9550757-B2 优先权日:2010-03-05 标题:Nuclear transport modulators and uses thereof 发明人:SHACHAM SHARON; KAUFFMAN MICHAEL; SANDANAYAKA VINCENT P; SHECHTER SHARON 权利人:KARYOPHARM THERAPEUTICS INC 摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).
专利号:WO-2008106286-A2 优先权日:2007-02-26 标题 :Perfluoroparacyclophane and methods of synthesis and use thereof
参考标题:Product Comprising At Least One Phosphatase Cdc25 Inhibitor Combined With At Least One Other Anticancer Agent 摘要:A Subject Of The Invention Is A Product Comprising At Least One Cdc25 Phosphatase Inhibitor In Combination With At Least One Other Anti-Cancer Agent For A Therapeutic Use Which Is Simultaneous, Separate Or Spread Over Time In The Treatment Of Cancer. According To The Invention, The Other Anti-Cancer Agent Is Preferably Chosen From: Analogues Of Dna Bases Such As 5-Fluorouracil; Type I And/or Ii Topoisomerase Inhibitors Such As For Example Camptothecin And Its Analogues, Doxorubicin Or Amsacrine; Compounds Interacting With The Cell Spindle Such As For Example Paclitaxel (Taxol); Compounds Acting On The Cytoskeleton Such As Vinblastine; Inhibitors Of The Transduction Of The Signal Passing Through The Heterotrimeric G Proteins; Prenyltransferase Inhibitors, And In Particular Farnesyltransferase Inhibitors; Cyclin-Dependent Kinase (Cdks) Inhibitors; Alkylating Agents Such As Cisplatin; Antagonists Of Folic Acid Such As Methotrexate; And Inhibitors Of The Synthesis Of Dna And Cell Division Cell Such As Mitomycin C. A Further Subject Of The Invention Is (1R)-1-[((2R)-2-Amino-3-[(8S)-8-(Cyclohexylmethyl)-2-Phenyl-5,6-Dihydroimidazo[1,2-A]Pyrazin-7(8H)-Yl]-3-Oxopropyl}Dithio)Methyl]-2-[(8S)-8-(Cyclohexylmethyl)-2-Phenyl-5,6-Dihydroimidazo[1,2-A]Pyrazin-7(8B)-Yl]-2-Oxoethylamine, Or A Pharmaceutically Acceptable Salt Thereof, Useful As An Anticancer Agent.
合成参考文献
参考文献:10.1007/3-540-68525-1_10 摘要:Richmond TG. Metal Reagents for Activation and Functionalization of Carbon-Fluorine Bonds. 1999. In: Activation of Unreactive Bonds and Organic Synthesis. : Springer Berlin Heidelberg; 1999. 参考文献:10.1007/s10965-013-0230-5 摘要:Krishnan R, Parthiban A. Semifluorinated multiple pendant group bearing poly(arylene ether) copolymers prepared at room temperature. Journal of Polymer Research. 2013 Jul 28;20(8):230. doi: 10.1007/s10965-013-0230-5. 参考文献:10.1134/s1070363212010197 摘要:Bazhin DN, Shchegol’kov EV, Kudyakova YS, Scherbakov KV, Burgart YV, Saloutin VI. Features of synthesis and structure of ethyl (2Z)-3-hydroxy-(2,3,4,5-tetrafluorophenyl)-propyl-2-enoate. Russian Journal of General Chemistry. 2012 Jan;82(1):116–21. doi: 10.1134/s1070363212010197.